GET DAILY SIGNALSCME Group (CME): Analyst Targets Suggest a Potential +12% Move to $330
Key Takeaways
- The central price target of $330 represents the arithmetic mean of six verified analyst price targets above the current share price; it is not an official published consensus.
- The most recent verified close for CME Group Inc. (CME) was roughly $293, so the stock would need to rise about 12% to reach $330.
- Across the 11 individual targets reviewed, the full range runs from $230 to $367, with an overall mean near $300—pointing to unusually wide disagreement among analysts.
- The strongest supports include record third-quarter trading volumes, double-digit revenue and earnings growth, and a durable market-data business.
- The biggest risks center on valuation after a strong rally, rising competition, and the possibility that trading volumes cool if market volatility normalizes.
- You can track this ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages to stay current on developments.
- Explore Trending AI Robots to see AI-driven tools that monitor thousands of stocks and ETFs for changing conditions.
Understanding the Analyst Price Targets
CME Group operates the world's largest derivatives marketplace, including the Chicago Mercantile Exchange, CBOT, NYMEX, and COMEX. Because targets vary so widely, the $330 figure is simply the average of the six verified targets sitting above the current price rather than a published Street consensus. The overall mean of all 11 targets reviewed comes in near $300, and the full range stretches from $230 (Bank of America Securities, Underperform) to $367 (J.P. Morgan, which upgraded the stock to Buy in late October 2026).
The dispersion stands out. On the bullish side, Morgan Stanley raised its target to $359 and Piper Sandler to $330, pointing to new products and a structural growth runway. UBS moved to $310 while keeping a Hold, and Raymond James held an Outperform view near $320. On the more cautious side, Goldman Sachs lifted its target to $271 but kept a Sell rating, Deutsche Bank downgraded to Hold on valuation grounds in August, and Barclays sits at $270. The gap between the highest and lowest targets reflects real disagreement over how much of CME's recent volume-driven growth will prove durable versus tied to temporary market volatility. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path to the Target
With the stock near $293 and the target at $330, the required advance is roughly 12%—a meaningful move rather than a modest drift. Notably, CME's 52-week range runs from $218.31 to $329.16, placing the $330 objective essentially at the stock's prior high.
The fundamental backdrop looks solid. Third-quarter 2026 revenue rose 13% to a record $1.74 billion, adjusted diluted EPS climbed 13% to $3.02, and average daily volume reached a third-quarter record of 29.4 million contracts, up 16%, with double-digit growth across all six asset classes. Market data revenue hit a record $243 million, marking its 34th consecutive quarter of growth. The path toward $330 would likely require continued volume momentum and successful adoption of initiatives such as the December 2026 CME Securities Clearing launch tied to the U.S. Treasury clearing mandate.
Factors That Could Support a Move Higher
Several elements could help the stock retake and exceed its prior high. Broad-based volume growth, including a 23% rise in equity-complex trading and 22% international ADV growth, supports clearing and transaction fees. The market-data franchise delivers recurring, high-margin revenue. New products such as single-stock futures, 24/7 gold and silver trading, and E-nano equity index futures offer incremental volume opportunities. Management also reported a record of roughly $100 billion in average daily capital efficiencies, which strengthens client stickiness. Finally, nearly $1 billion returned to shareholders in the quarter through dividends and buybacks highlights strong cash generation. From what I see, these elements provide a constructive foundation.
Risks That Could Keep the Target Out of Reach
Valuation remains the central concern. The stock trades near 24 times trailing earnings after a sharp rally, leaving little room for disappointment, and Deutsche Bank's valuation-driven downgrade reflects this reality. Competition is increasing, with Bank of America highlighting Intercontinental Exchange (ICE) in energy and BGC Group (BGC) in rates as potential threats to market share. Because so much recent growth ties to market uncertainty, a period of calmer markets could slow volume growth. Higher equity volumes also raise license-fee costs, which could limit margin expansion, and a high dividend payout ratio has prompted questions about sustainability.
Technical Levels and Market Structure
The $330 target is also a meaningful technical level: it sits just above the 52-week high of $329.16 set in March 2026, which now serves as the key resistance zone. A sustained move through that area would mark a breakout to new highs. On the downside, the stock's recent action near the $278–$279 zone (around its 50-day moving average) offers nearby support, with the 52-week low of $218.31 representing the deeper structural floor. The long-term trend remains upward, but the stock is currently consolidating below its prior peak. I'm watching this closely as the consolidation plays out.
Time Horizon and Key Items to Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual analysts apply different time frames. Investors should watch the December 2026 CME Securities Clearing launch and subsequent adoption, monthly volume and open-interest reports, and fourth-quarter earnings, where consensus points to sequentially lower EPS. Ongoing analyst revisions—several firms adjusted targets right after the October earnings report—and the cloud migration to Google Cloud are also worth tracking, along with interest-rate and volatility conditions that drive trading activity.
Final Assessment
The question of whether CME can reach $330 ultimately comes down to whether its record volume and data growth can overcome valuation skepticism. The target—an average of the six above-price analyst targets—implies a roughly 12% advance that would return the stock to its 52-week high. Record volumes, a durable data franchise, and new product initiatives provide genuine support, while rich valuation, competitive pressure, and volatility dependence remain the principal obstacles. The wide $230-to-$367 analyst range underscores that this is far from a settled debate, and investors should monitor volume trends, the securities clearing launch, and upcoming earnings before drawing conclusions.
Using AI Daily Buy/Sell Signals for Ongoing Monitoring
For a more systematic view of shifting conditions, I find Tickeron's AI Daily Buy/Sell Signals helpful. These tools use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. This approach can help investors discover new opportunities, monitor existing positions, and spot emerging trends more efficiently than manual review alone. I consider exploring these signals as a useful complement to traditional research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
CME sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for CME moved above the 200-day moving average on October 26, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on CME as a result. In 57 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
The Moving Average Convergence Divergence (MACD) for CME just turned positive on October 08, 2026. Looking at past instances where CME's MACD turned positive, the stock continued to rise in 25 of 47 cases over the following month. The odds of a continued upward trend are 53%.
CME moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CME crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +3.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where CME advanced for three days, in 170 of 341 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
The Aroon Indicator entered an Uptrend today. In 138 of 265 cases where CME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Bearish Trend Analysis
The 10-day RSI Indicator for CME moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In 19 of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at 45%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 41%.
CME broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. CME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.979) is normal, around the industry mean (3.999). P/E Ratio (24.766) is within average values for comparable stocks, (18.165). CME's Projected Growth (PEG Ratio) (4.578) is very high in comparison to the industry average of (1.780). Dividend Yield (0.018) settles around the average of (0.018) among similar stocks. CME's P/S Ratio (14.535) is slightly higher than the industry average of (7.166).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of securities and commodity exchanges
Industry FinancialPublishingServices
Advertisement